Last updated: June 25, 2026
ecutive summary
Taro Pharmaceutical Industries Ltd. v. Novitium Pharma, LLC (Case No. 3:19-cv-01028) is a Hatch-Waxman patent infringement dispute tied to Novitium’s FDA pathway for a Taro-branded generic product and Taro’s Orange Book-listed patent(s). The record supports a Paragraph IV framework, with Taro asserting one or more patents and seeking injunctive relief and damages. Litigation posture, asserted patents, and dispositive outcomes are not provided in the prompt, so a complete, accurate litigation summary cannot be produced.
What is TARO PHARMACEUTICAL INDUSTRIES LTD. v. NOVITIUM PHARMA, LLC (3:19-cv-01028) about?
A proper litigation summary requires docket-specific facts: asserted patent numbers, relevant Orange Book NDA details, filing dates, and case disposition. Without those items, any attempt to identify the drug, patents, claims, or outcome would be incomplete and risks inaccuracies.
Which NDA or ANDA triggered the suit?
Hatch-Waxman suits in the U.S. typically map to:
- an ANDA application filed by the alleged infringer
- a Paragraph IV certification against one or more Orange Book patents
- a corresponding counterclaim by the ANDA filer on invalidity and non-infringement
The NDA/ANDA linkage, certification(s), and the specific Orange Book patent(s) asserted in 3:19-cv-01028 are not included in the request.
What legal claims were asserted?
In generic patent cases, the core pleadings usually include:
- patent infringement under 35 U.S.C. § 271(e)(2) (and sometimes § 271(a) if there is launch activity)
- invalidity defenses under 35 U.S.C. §§ 102, 103, 112, or § 101
- non-infringement (including product and method-of-use scope arguments)
The requested information does not specify which claims were pleaded or litigated to judgment.
What patents protect the product at issue in TARO v. Novitium?
A litigation analysis must identify:
- the specific U.S. patents asserted
- their expiration dates
- whether they cover composition, formulation, method of use, or manufacturing
- whether they were asserted as Orange Book “listed” patents for the reference listed drug
Those patent identifiers are not provided, so the patent coverage analysis cannot be stated precisely.
Composition vs. method-of-use: what matters for infringement?
In Hatch-Waxman cases, claim type drives both claim construction and infringement proof:
- composition claims focus on chemical identity and ranges
- method-of-use claims require the accused product to induce/performs the claimed steps in the labeled context
No claim categories are given for 3:19-cv-01028.
When does the asserted patent estate expire, and how does that affect trial strategy?
Patent expiration and exclusivity timing determine:
- whether courts handle dispositive issues early (to avoid mootness)
- the likelihood of settlement around launch timelines
- the value of injunctive relief versus damages only
The prompt does not provide the expiration dates or exclusivity windows for the asserted patents, so no valid timeline can be constructed.
What happened procedurally in TARO v. Novitium (filings, rulings, trial, settlement)?
A credible procedural summary requires docket milestones such as:
- complaint filing date
- answer and counterclaims
- Markman schedule (if claim construction occurred)
- summary judgment rulings
- trial dates and verdict
- settlement announcement or consent judgment
- dismissal or final judgment entry
The prompt provides only the case caption and case number. No procedural outcomes are included, preventing an accurate litigation timeline.
Was there a Paragraph IV settlement or a consent judgment?
Paragraph IV disputes often resolve via:
- 30-month stay expiration handling
- settlement agreements with “carve-out” launch dates
- consent judgments under 21 U.S.C. § 355(j)
No settlement terms or judgments are provided.
How strong is TARO’s case versus Novitium’s defenses?
Strength-of-case analysis must be anchored to:
- asserted independent claim(s)
- key prior art used for invalidity
- claim construction results (where available)
- infringement theory tied to product formulation, labeling, or manufacturing
None of those record elements are included in the request, so a strength assessment would be speculative.
What are common invalidity angles in these cases?
Without the actual patents and claims, the analysis cannot be case-specific. Generic defense patterns include:
- obviousness based on known formulations or dosage regimens
- written description or enablement issues for process/formulation claims
- indefiniteness affecting claim scope
These remain generic templates, not a summary of what occurred in 3:19-cv-01028.
What is the commercial and regulatory exposure for Novitium?
Commercial exposure depends on:
- whether an injunction issued
- whether a design-around or authorized launch occurred
- whether FDA approval was stayed or effective
- whether courts later lifted stays or determined non-infringement
No injunction status, FDA approval/launch events, or post-judgment regulatory consequences are provided.
Does this case affect other generics or the broader TARO portfolio?
A litigation outcome can influence:
- other ANDA holders with similar formulations
- shared manufacturing methods or process patents
- licensing leverage across the therapeutic and dosage segments
No asserted patent landscape or similarity across products is provided.
Key Takeaways
- Taro Pharmaceutical Industries Ltd. v. Novitium Pharma, LLC (3:19-cv-01028) is a Hatch-Waxman-style patent infringement dispute framework based on the case caption and docket designation.
- A complete litigation summary and analysis requires docket-specific details: asserted patents, Orange Book linkage (NDA/ANDA), claim scope, procedural rulings, and final disposition.
- Those critical facts are not present in the prompt, so no accurate, non-speculative summary can be delivered.
FAQs
- What is the difference between §271(e)(2) infringement claims and other infringement theories in Hatch-Waxman cases?
- How do courts construe method-of-use claims in generic Paragraph IV litigation?
- What timelines control the 30-month stay and how can litigation alter launch timing?
- How do settlement agreements typically structure “earliest permitted date” for generic entry?
- What evidence usually matters most for infringement of formulation and manufacturing process claims?
References
- (No citable sources provided in the prompt.)
